Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1386-1393 , November 2009

Failure to Achieve a Threshold Dose of CD34+CD110+ Progenitor Cells in the Graft Predicts Delayed Platelet Engraftment after Autologous Stem Cell Transplantation for Multiple Myeloma

  • Craig T. Wallington-Beddoe

      Affiliations

    • Hematology Department, Westmead Hospital, Sydney, Australia
    • University of Sydney, Sydney, Australia
    • Corresponding Author InformationCorrespondence and reprint requests: Craig T. Wallington-Beddoe, BSc (Hons), MB BS (Hons), Hematology Department, Westmead Hospital, Hawkesbury Road, Westmead, Sydney NSW 2145, Australia.
    • ,
  • David J. Gottlieb

      Affiliations

    • Hematology Department, Westmead Hospital, Sydney, Australia
    • Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney, Australia
    • University of Sydney, Sydney, Australia
    • ,
  • Fran Garvin

      Affiliations

    • Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney, Australia
    • ,
  • Vicki Antonenas

      Affiliations

    • Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney, Australia
    • ,
  • Mary M. Sartor

      Affiliations

    • Flow Cytometry Unit, Westmead Hospital, Sydney, Australia

Received 18 March 2009 ,Accepted 26 June 2009.

References 

  1. Kyle R, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972
  2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520
  3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Francophone du Myelome. N Engl J Med. 1996;335:91–97
  4. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol. 2008;83:614–617
  5. Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39:279–283
  6. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65
  7. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–2502
  8. Meldgaard Knudsen L, Jensen L, et al. Subsets of CD34+ hemopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica. 1999;84:517–524
  9. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588–596
  10. Ramsfjell V, Borge OJ, Cui L, Jacobsen SE. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38−) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol. 1997;158:5169–5177
  11. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 1995;74:521–525
  12. Sartor M, Garvin F, Antonenas V, et al. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant. 2007;40:851–857
  13. Sartor M, Antonenas V, Garvin F, et al. Recovery of viable CD34+ cells from cryopreserved haemopoietic progenitor cell products. Bone Marrow Transplant. 2005;36:199–204
  14. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213–226
  15. Maharaj D, Steinberg JP, Gouvea JV, Gieser PW. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant. Bone Marrow Transplant. 1999;23:539–548
  16. Dercksen MW, Rodenhuis S, Dirkson MK, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol. 1995;13:1922–1932
  17. Feng R, Shimazaki C, Inaba T, et al. CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:1217–1222

 Financial disclosure: See Acknowledgments on page 1392.

PII: S1083-8791(09)00302-4

doi: 10.1016/j.bbmt.2009.06.018

Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1386-1393 , November 2009

Article Tools

* Image Usage & Resolution